Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan

Gilead Sciences’ hepatitis C therapy Harvoni (ledipasvir + sofosbuvir) posted sales of 296,049 million yen in 2016 in Japan (+151.7% over the previous year) and was the top-selling drug in the country, according to data released by IMS Japan on...read more